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Regulatory T (Treg) cells expressing forkhead box P3 (Foxp3) arise during thymic selection among thymocytes with
modestly self-reactive T cell receptors. In vitro studies suggest Foxp3 can also be induced among peripheral CD4
þ T
cells in a cytokine dependent manner. Treg cells of thymic or peripheral origin may serve different functions in vivo, but
both populations are phenotypically indistinguishable in wild-type mice. Here we show that mice with a Carma1 point
mutation lack thymic CD4
þFoxp3
þ Treg cells and demonstrate a cell-intrinsic requirement for CARMA1 in thymic Foxp3
induction. However, peripheral Carma1-deficient Treg cells could be generated and expanded in vitro in response to the
cytokines transforming growth factor beta (TGFb) and interleukin-2 (IL-2). In vivo, a small peripheral Treg pool existed
that was enriched at mucosal sites and could expand systemically after infection with mouse cytomegalovirus (MCMV).
Our data provide genetic evidence for two distinct mechanisms controlling regulatory T cell lineage commitment.
Furthermore, we show that peripheral Treg cells are a dynamic population that may expand to limit immunopathology
or promote chronic infection.
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Introduction
Two major mechanisms enforce self-tolerance: negative
selection in the thymus and dominant tolerance in the
periphery. The importance of both mechanisms is under-
scored by the phenotypes of autoimmune regulator (Aire)
knockout [1] and scurfy mice [2], which have defects in
negative selection or dominant tolerance, respectively.
Humans with orthologous mutations develop autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED) [3,4] or immune dysregulation, polyendocrinop-
athy, enteropathy, X-linked (IPEX) syndrome [5]. These
mutations all result in systemic autoimmunity, though defects
in dominant tolerance cause a more severe and fatal disease.
The study of dominant tolerance accelerated after cloning of
the scurfy locus, which identiﬁed forkhead box P3 (Foxp3) as
an essential molecule [6]. Foxp3 is a transcription factor
expressed predominantly in CD4
þ T cells committed to the
regulatory T cell (Treg) lineage [7]. Expression of Foxp3
programs T cells with suppressor function, allowing Treg cells
to effect dominant tolerance [8].
The majority of Treg cells are derived from the thymus,
although an unknown percentage of these cells may develop
in the peripheral lymphoid organs. Thymic Treg lineage
commitment occurs in CD4 single-positive (SP) thymocytes
and requires intermediate afﬁnity binding of the T cell
receptor (TCR) [9], co-stimulation through CD80 and CD86
interactions with CD28 [10,11], and the cytokines TGFb [12]
and interleukin (IL)-2 or IL-15 signaling through the shared
IL-2Rb chain [13–16]. Peripheral commitment of naı ¨ve CD4
þ
T cells to the Treg lineage, modeled in vitro, requires
exogenous TGFb, in addition to TCR stimulation and
concomitant IL-2 production, to induce Foxp3 expression
and Treg function [17]. Foxp3 induction can be enhanced in
vitro by inhibition of AKT-mediated signaling or transient
TCR stimulation [18,19], and may be preferentially driven in
vivo by retinoic acid made by macrophages and dendritic
cells (DCs) residing in mucosal tissues [20]. The differences in
signaling pathways used in the development of thymic versus
peripherally induced Treg cells remain largely unexplored.
In this report, we describe the characterization and
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PLoS BIOLOGYpositional cloning of the king mutation. We identiﬁed the
mutation by screening G3 mice, homozygous for germline
mutations induced by N-ethyl-N-nitrosourea (ENU) [21], to
detect defects in T cell effector function. In king homozygous
mice, no thymic Treg cells were detected, but Foxp3 could be
induced among peripheral CD4
þ T cells in response to
cytokines. Thus, the king mouse offered a model to explore
differences in signaling pathways used for thymic versus
peripheral Treg lineage commitment and to study peripheral
Treg dynamics, which are normally obscured by the presence
of thymic-derived Treg cells. Our studies provide genetic
evidence of two pathways, operating in the thymus or
periphery, that commit CD4
þ T cells to the Treg lineage. We
also show that viral infection can cause massive expansion of
peripheral Treg cells, an event that may reduce immunopa-
thology or contribute to persistent viral infections.
Results
Identification of the king Mutation
To identify genes with non-redundant roles in T cell
development, priming or effector function, we designed a
screen to detect defective cytotoxic CD8
þ T cell (CTL)
responses in mice immunized with ovalbumin (act-mOVA)
[22]. Among 2,500 ENU-mutagenized G3 mice screened, we
have thus far bred three non-responsive mutations to
homozygosity. We termed one of these mutants king. While
the primary screen used was an in vivo cytotoxicity assay [23],
the mutation could be scored using an in vitro assay as well.
To do so, we isolated T cells 7 d after immunization, at the
peak of the CD8
þ T cell response, and expanded antigen-
speciﬁc CD8
þ T cells in culture with SIINFEKL peptide. king
CD8
þ T cells did not undergo secondary expansion or
produce interferon (IFN)c after restimulation with peptide
(Figure 1A). We hypothesized that a mutation affecting DC
cross-priming of CD8
þ T cells, T cell activation, or T cell
proliferation could cause such a phenotype. To test DC
function, we used FMS-like tyrosine kinase 3 (Flt3)-ligand to
generate bone marrow-derived lymphoid DCs, a subset of
DCs that efﬁciently cross-primes CD8
þ T cells [22]. When
lymphoid DCs were exposed to ovalbumin expressing
apoptotic cells, king DCs primed ovalbumin-speciﬁc OT-I T
cells as efﬁciently as wild-type DCs (Figure 1B). In addition,
king DCs showed normal up-regulation of co-stimulatory
molecules CD40, CD80, CD86, and major histocompatibility
complex (MHC) class I and II after activation by Toll-like
receptor ligands [24] or apoptotic cells [22] (unpublished
data), suggesting that the mutation did not affect co-
stimulation. These results indicated that the king mutation
did not impair DC-mediated cross-priming of CD8
þ T cells.
We next investigated T cell activation. king CD4
þ and CD8
þ
T cells normally up-regulated CD69, but not CD25 (IL-2Ra)
upon TCR activation (Figure 1C). As CD25 can be further up-
regulated in response to IL-2, we measured IL-2 production by
king CD4
þ T cells activated by TCR ligation and found a lack
thereof (Figure 1D). Since these data implied only a partial
defect in T cell activation, we next assessed T cell proliferative
capacity. king T cells failed to proliferate in response to TCR
stimulation, although this could be partially rescued by
exogenous IL-2 (Figure 1E). As IL-2 is required to maintain
CD4
þCD25
þFoxp3
þ Treg cells in the periphery [14], we assessed
the development of these cells in king mice. CD4
þFoxp3
þ T
cells were reduced by an order of magnitude in periphery
(Figure 1F), but were absent in the thymus (Figure 1G),
indicating that the king mutation blocked commitment of
developing thymocytes to the Treg lineage. We also investigated
the function of another population of self-reactive T cells that
develop in the thymus, natural killer T (NKT) cells. 90 min
after injection of the NKT cell-speciﬁc agonist alpha-galacto-
sylceramide (aGalCer), elevated concentrations of IL-4 and
IFNc were measured in the serum of king mice, indicating that
the mutation did not impair pan-T cell function (Figure 1H).
Unlike most other mutations that impair Treg development,
king mice did not exhibit gross signs of autoimmunity. Even in
a cohort of king mice monitored for over 9 mo, no detectable
anti-chromatin auto-antibodies (Figure S1) were found in the
serum, nor did the mice develop splenomegaly, lymphopro-
liferative disease, or signs of chronic inﬂammation—all
aspects of autoimmunity normally controlled by Treg cells.
king, a Mutation in Carma1
To ﬁnd the causative mutation, we mapped the king
phenotype by outcrossing the king stock (C57BL/6J back-
ground) to C3H/HeN mice, backcrossing to the king stock, and
measuring the percentage of circulating CD4
þ T cells
expressing Foxp3 in the blood of F2 mice (Figure 2A). By
analyzing 134 informative microsatellite markers dispersed
throughout the genome on 39 meioses, we localized the king
mutation to the distal region of Chromosome 5 with a peak
logarithm of odds (Lod) score of 11.74 (Figure 2B). Further
analysis of 268 meioses conﬁned the mutation to a 1.03-Mb
critical region, bounded by the markers D5Mit292 and
D5Mit101. This region contained only six annotated genes
(http://www.informatics.jax.org), and among these was Card11
(more commonly known as Carma1 [from CARD-MAGUK1]).
We sequenced either genomic DNA or cDNA of all coding
basepairs within the critical region and identiﬁed a single
point mutation in Carma1 (Figure 2C), which resulted in an
L525Q substitution. The mutation occurred in a-helix2, in the
NORS (no regular secondary structure) domain, of the
CARMA1 linker region (Figure 2D). In naı ¨ve T cells, the
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Author Summary
In mammals, CD4
þ T cells are essential for controlling infections, but
have the potential to attack host tissues as well, resulting in
autoimmune disease. A subset of CD4
þ T cells, regulatory T cells
(Treg)—identified by the expression of the forkhead transcription
factor Foxp3—serve to prevent immunopathology by dampening
immune responses. These cells are unique among CD4
þ T cell
subsets, as only the Treg lineage can develop in both the thymus and
periphery. Using a genetic approach, we identified a mutation in the
gene Carma1, a key component of T and B cell signaling, which in
mice distinguishes Treg cells derived from the periphery from
thymic-derived regulatory T cells. The mutation caused an absence
of thymic Treg cells. However, a small population of Treg cells was
observed in the spleen, lymph nodes, and colon of Carma1-mutant
mice that expanded after viral infection, suggesting that peripheral
development of Treg cells could still occur. Indeed, Carma1-mutant
CD4
þ T cells could be converted into the Treg lineage in vitro. Our
results demonstrate an organ-specific requirement for the CARMA1
signaling pathway that developing thymocytes need in order to
become Treg cells, but that naı ¨ve CD4
þ T cells can bypass in the
periphery. This dichotomy suggests that Treg cells of thymic or
peripheral origin may have different specificities or functions in vivo.CARMA1 protein adopts a conformation in which the linker
domain associates with the caspase recruitment domain
(CARD). Upon T cell activation, protein kinase C (PKC)h
phosphorylation of residues in the linker domain reduces
intramolecular afﬁnity for the CARD domain. This liberates
both the CARD and coiled-coil domains, allowing CARMA1
oligomerization and recruitment of B cell CLL/lymphoma 10
(BCL10) and mucosa associated lymphoid tissue lymphoma
translocation gene 1 (MALT1) to the CARMA1 signaling
module [25,26]. Following activation, degradation of BCL10
terminates CARMA1-dependent signaling [27]. CARMA1 has a
similar function in B cells, downstream of PKCb. No CARMA1
expression was detected by western analysis in the thymus,
spleen, or lymph nodes of king homozygotes (Carma1
k/k) (Figure
2E). Furthermore, CARMA1 was not detectable in CD4 or CD8
SP thymocyte lysates (Figure 2F). The L525Q mutation may
have the effect of destabilizing the CARMA1-king protein or
marking it for degradation in mature T and B cells.
Several other groups have generated targeted knockouts or
hypomorphs of Carma1 [28–31]. Like these other mutant
mice, Carma1
k/k mice have reduced basal serum immunoglo-
bulin levels (Figure S2A), fail to mount antigen-speciﬁc
immunoglobulin (Ig)M and IgG responses after immunization
with ovalbumin in Complete Freunds Adjuvant (Figure S2B),
and exhibit impaired B cell proliferation (Figure S2C).
Lymphocyte development was abnormal in Carma1
k/k mice,
as in other Carma1 mutants, including a deﬁciency in
peritoneal B1 cells and skewed double-negative thymocyte
populations (Figure S3A–S3D). Additionally, splenic natural
killer (NK) cells, NKT cells, cd T cells, memory CD4
þ T cells,
and mature B cells were reduced in both percentage and cell
number (Figure S3E–S3L and unpublished data). With age,
some Carma1
k/k mice developed severe dermatitis, as reported
in homozygotes for the unmodulated allele of Carma1 [30].
Collectively, these data suggest that the L525Q king mutation
Figure 1. The king Mutation Impairs T Cell Activation and Treg Development
(A) Activation of CD8
þ T cells after immunization with c-irradiated act-mOVA splenocytes.
(B) Cross-presentation of ovalbumin epitopes to OT-I T cells by Flt3L-matured bone marrow-derived dendritic cells (BMDCs).
(C) Expression of T cell activation markers CD25 and CD69 (intracellular), 24 h after activation of purified CD4
þ T cells.
(D) Production of IL-2 by CD4
þ T cells 18 h after activation.
(E) Proliferation of CD4
þ T cells, 96 h after activation.
(F,G) CD4 and Foxp3 expression in total (F) splenocytes and (G) thymocytes. Standard deviation is indicated.
(H) Serum concentrations of IL-4 and IFNc 90 min after injection with aGalCer. Error bars indicate standard deviation.
These experiments were each repeated at least three times with consistent results and representative data are presented.
doi:10.1371/journal.pbio.1000051.g001
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CARMA1 in Treg Developmentabolishes CARMA1 activity, and uncover an essential require-
ment for CARMA1 in thymic Treg development.
A Cell-Intrinsic Role for Carma1 in Treg Lineage
Commitment
In addition to Foxp3, thymocytes committed to the Treg
lineage also express CD25, glucocorticoid-induced tumor
necrosis factor receptor (GITR), and cytotoxic T-lymphocyte
antigen-4 (CTLA-4) [32]. To determine whether Carma1
k/k
thymocytes begin differentiation into the Treg lineage but fail
to express Foxp3, a distal marker of Treg differentiation, we
examined expression of these additional markers (Figure 3A).
The lack of expression of these markers suggests CARMA1 acts
early in Treg lineage commitment. An absence of thymic Treg
cells in Carma1
k/k mice could result from altered selection by
thymic epithelial cells, a defect in the TCR and co-stimulatory
signaling pathways, or a lack of signaling through the IL-2Rb
chain [13,15,16,33]. To understand the role of Carma1 in thymic
Treg development, we generated reciprocal and mixed bone-
marrow chimeric mice. Foxp3 expression was absent in
Carma1
k/k thymocytes that developed in a wild-type thymus
(Figure 3B), but normal in wild-type thymocytes that developed
in a Carma1
k/k thymus (Figure 3C). Therefore, the Treg
deﬁciency in Carma1
k/k mice results not from an altered thymic
environment, but rather from an intrinsic defect in hema-
topoietically derived precursors. When wild-type mice were
reconstituted with Carma1
k/k and wild-type bone marrow at a
4:1 ratio, 1:1 chimerism was achieved among lymphocytes.
While wild-type thymocytes differentiated into the Treg lineage
at normal frequencies, Carma1
k/k thymocytes failed to develop
into thymic Treg cells and expressed lower levels of CD25,
GITR, and CTLA-4 among CD4 SP thymocytes (Figure 3D). As
trans-acting IL-2Rc chain cytokines produced by wild-type
thymocytes did not rescue Foxp3 induction in Carma1
k/k
thymocytes, it is likely that impaired signaling downstream of
the TCR or CD28 underlies the absence of the thymic Treg cells.
Pathways distinct from those involved in thymic develop-
ment regulate commitment and homeostasis of peripheral
Treg cells [14]. In wild-type mice reconstituted with Carma1
k/k
Figure 2. Positional Cloning of the king Mutation
(A) Percentage of circulating CD4
þ T cells expressing Foxp3 in king homozygous and heterozygous mice.
(B) Linkage of the king phenotype to Chromosome 5, using 134 informative microsatellite markers.
(C) Genomic sequence of Carma1 in wild-type and king mice, with corresponding amino acid sequence.
(D) Diagram of the CARMA1 protein (star, king mutation; a-helices, indicated by rings). Abbreviations: NORS, no regular secondary structure; SH3, Src
homology 3; GUK, guanylate kinase.
(E) Western blot analysis of CARMA1 expression in thymus, spleen, and lymph node lysates.
(F) CARMA1 expression in CD4
þCD8
 CD3e
þ (CD4 SP) and CD4
 CD8
þCD3e
þ (CD8 SP) sorted thymocytes.
doi:10.1371/journal.pbio.1000051.g002
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CARMA1 in Treg Developmentbone marrow, peripheral Treg cells were found at reduced
frequencies, similar to those observed in Carma1
k/k mice
(Figure 3E). Conversely, in Carma1
k/k mice reconstituted with
wild-type bone marrow, peripheral CD4
þFoxp3
þ Treg cells
occurred at frequencies similar to those observed in wild-type
mice (Figure 3F). Therefore, the Carma1
k/k environment can
support Treg homeostasis and a cell-intrinsic defect in
development causes the Treg deﬁciency observed in these
mice. It has been proposed that IL-2 regulates Treg homeo-
stasis and that Treg cells may function as an IL-2 ‘‘sink’’
[14,34]. However, in wild-type mice reconstituted with mixed
wild-type and Carma1
k/k bone marrow, the Carma1
k/k Treg
population did not expand in the periphery (Figure 3G).
Interestingly, the wild-type Treg population expanded to
comprise 20% of the wild-type CD4
þ T cells, and 10% of the
total CD4
þ T cell pool. This suggests that a cell-extrinsic
homeostatic mechanism regulates the size of the Treg
compartment in the periphery of naı ¨ve wild-type mice.
TGFb and IL-2 Drive CARMA1-Independent Foxp3
Induction
While Carma1
k/k mice lack thymic Treg cells, they do exhibit
a peripheral Treg pool, though it is substantially smaller than
that in wild-type mice. Peripheral expansion and conversion
of CD4
þFoxp3
þ T cells can be modeled in vitro by culturing
activated CD4
þ T cells in the presence of the cytokine TGFb
[17]. When we activated Carma1
k/k CD4
þ T cells with plate-
bound anti-CD3 and anti-CD28 in the presence of exogenous
TGFb, they did not proliferate or express Foxp3. However,
the combination of exogenous IL-2 and TGFb was sufﬁcient
to rescue both proliferation and Foxp3 induction (Figure 4A).
Importantly, the percentage and number of undivided
Carma1
k/k CD4
þFoxp3
þ T cells increased, indicating that
Foxp3 expression was induced from CD4
þFoxp3
  T cells.
Additionally, the induced Carma1
k/k Treg cells did not express
stable CARMA1 protein (Figure S4).
To determine whether Carma1
k/k CD4
þT cells were more or
less prone than wild-type cells to express Foxp3, we
preformed a dose-response analysis of Foxp3 induction by
titrating anti-CD3, anti-CD28, and TGFb concentrations. In
the absence of CARMA1, the TCR-signaling threshold for
Foxp3 induction was increased signiﬁcantly (Figure 4B). Co-
stimulatory signals were also required for efﬁcient Foxp3
induction in wild-type and Carma1
k/k CD4
þT cells (Figure 4C).
CARMA1 deﬁciency did not alter the ability of CD4
þ T cells
Figure 3. A Cell-Intrinsic Requirement for Carma1 in Treg Development
(A) Expression of Treg markers in CD4 SP thymocytes.
(B,C) Foxp3 expression in Carma1
k/k (CD45.2
þ) and C57BL/6.SJL (CD45.2
 ) CD4 SP thymocytes, reconstituted in C57BL/6.SJL (CD45.2
 )o rCarma1
k/k
(CD45.2
þ) mice. The percentage of CD4 SP thymocytes expressing Foxp3 is shown.
(D) Analysis of Treg markers in wild-type mice reconstituted with mixed Carma1
k/k (CD45.2
þ) and C57BL/6.SJL (CD45.2
 ) bone marrow. The percentage of
CD4 SP thymocytes of C57BL/6.SJL or Carma1
k/k origin expressing each marker is shown in blue or red, respectively.
(E–G) Using the same mice, the percentage of splenic CD4
þ T cells expressing Foxp3 in reciprocal (E,F) and mixed (G) bone marrow chimeric mice is
shown. B6 denotes C57BL/6.SJL mice.
Five reconstituted mice were analyzed for each experiment. Standard deviation is indicated.
doi:10.1371/journal.pbio.1000051.g003
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CARMA1 in Treg Developmentto respond to limiting concentrations of TGFb (Figure 4D).
These data suggest that Foxp3 induction can occur without
CARMA1, and reveal a partial role for CARMA1 in trans-
mitting TCR-mediated signals for peripheral Foxp3 induc-
tion.
The absence of detectable thymic Treg cells and presence of
a small peripheral Treg population in Carma1
k/k mice suggests
that induction of Treg cells can occur in the periphery of
naı ¨ve mice without activation of the CARMA1 pathway. Also
consistent with this conclusion, Carma1
k/k mice had elevated
numbers of CD4
þFoxp3
þ T cells in the lamina propria and
mesenteric lymph nodes (Table 1). The lamina propria of the
colon is a site where peripheral conversion of Treg cells may
preferentially occur, and these lymphocytes drain to the
mesenteric lymph nodes [20,35]. The CD4
þFoxp3
þTreg cells in
Carma1
k/k mice showed normal expression of CD25, CTLA-4,
and GITR, but interestingly expressed higher amounts of
membrane-associated TGFb in the mesenteric lymph nodes
but not in the spleen (Figure 5A). In vitro induced Carma1
k/k
Treg cells showed a similar phenotype (Figure 5B) and
released more soluble TGFb than wild-type Treg cells in
culture, with or without activation (Figure 5C). Together,
these data suggest that peripheral induction of CD4
þFoxp3
þ
Treg cells occurs in the absence of Carma1.
Characterization of Carma1-Independent Foxp3 Induction
As IL-2 and TGFb are sufﬁcient to induce Foxp3 in
Carma1
k/k CD4
þ T cells, we explored the possibility that these
cytokines activated signaling pathways downstream of CAR-
MA1, or induced Foxp3 expression via an alternative path-
way. We ﬁrst activated wild-type and Carma1
k/k CD4
þ T cells
with the PKC activator phorbol myristate acetate (PMA) and
ionomycin, without exogenous cytokines (Figure 6A). Upon
activation, BCL10 phosphorylation, NF-jB inhibitor alpha
(IjBa) degradation and phosphorylation of both Jun N-
terminal kinase (JNK) isoforms occurred in wild-type T cells.
In contrast, BCL10 was constitutively phosphorylated,
amounts of IjBa were constantly elevated, and the JNKp54
isoform remained unphosphorylated in Carma1
k/k T cells.
Interestingly, decreased abundance and constitutive phos-
phorylation of BCL10 was observed in total Carma1
k/k lymph
node T cells, but not thymocytes (Figure 6B). Normally,
BCL10 is recruited to CARMA1 after activation. After
assembly of the CARMA1 signaling complex, phosphorylation
marks BCL10 for ubiquitination and degradation [27]. The
lack of CARMA1 protein (Figure 2D) and constitutive
degradation of BCL10 in Carma1
k/k T cells indicates that the
CARMA1 signaling complex cannot be assembled; this is also
reﬂected by the elevated amounts of TGFb-activated kinase 1
(TAK1) in resting and activated Carma1
k/k T cells (Figure 6A),
likely due to reduced protein turnover.
Other groups have reported that Carma1-deﬁcient T cells
exhibit a lack of nuclear factor jB (NF-jB) nuclear trans-
location [28–31] and JNK2 phosphorylation [36] after TCR
stimulation. While the CARMA1 signaling complex was
inoperative in Carma1
k/k mice, it was possible that exogenous
IL-2 and TGFb retained the ability to activate NF-jB or JNK.
However, when we activated wild-type and Carma1
k/k T cells
Table 1. Distribution of Treg Cells in Carma1
k/k Mice
Organ C57BL/6 Carma1
k/k
Thymus 0.39 6 0.10% 0.002 6 0.001%
Spleen 13.3 6 1.4% 0.47 6 0.06%
mLN 12.6 6 0.8% 0.96 6 0.06%
smLN 14.1 6 1.5% 0.61 6 0.16%
siLN 12.4 6 1.7% 0.32 6 0.07%
Colon LP
a 22.5% 8.4%
The percentage of CD4
þ cells expressing Foxp3 is indicated, along with standard
deviation. Five 8-wk-old C57BL/6 and Carma1
k/k mice were analyzed.
aTissues from three mice were pooled.
LP, lamina propria; mLN, mesenteric lymph node; siLN, superficial inguinal lymph node;
smLN, submandibular lymph node.
doi:10.1371/journal.pbio.1000051.t001
Figure 4. Cytokine Driven Induction of Foxp3 Does Not Require Carma1
(A) Proliferation and Foxp3 induction in CD4
þ T cells activated with anti-
CD3 (2 lg/ml) and anti-CD28 (2 lg/ml) antibody for 90 h in the presence
of IL-2 (100 U/ml) and/or TGFb (5 ng/ml).
(B–D) Dose response analysis of Foxp3 induction in CD4
þT cells activated
for 90 h with (B) indicated concentrations of anti-CD3 antibody, in the
presence of TGFb (5 ng/ml) and IL-2 (100 U/ml); with (C) indicated
concentrations of anti-CD28 antibody, in the presence of anti-CD3 (1 lg/
ml), TGFb (5 ng/ml), and IL-2 (100 U/ml); or with (D) indicated
concentrations of TGFb, in the presence of anti-CD3 (1 lg/ml), anti-
CD28 (1 lg/ml), and IL-2 (100 U/ml).
These experiments were each repeated at least three times with
consistent results and standard deviation is shown.
doi:10.1371/journal.pbio.1000051.g004
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CARMA1 in Treg Developmentwith PMA and ionomycin in the presence of these cytokines,
levels of IjBa degradation and JNK phosphorylation re-
mained unchanged up to 60 min after activation (unpub-
lished data). Similar results were obtained when T cells were
activated by anti-CD3 and anti-CD28 antibodies.
We next investigated whether other cytokines could drive
Foxp3 expression. To determine if trans-acting cytokines
produced by wild-type CD4
þ T cells could drive Foxp3
induction, we co-cultured activated wild-type and Carma1
k/k
CD4
þ T cells in the presence of TGFb. The presence of
activated wild-type cells allowed proliferation and Foxp3
induction in Carma1
k/k CD4
þ Tc e l l s .C o - c u l t u r ei nt h e
presence of IL-2 neutralizing antibody abolished prolifer-
ation of Carma1
k/k CD4
þ T cells and Foxp3 induction in both
wild-type and Carma1
k/k CD4
þ T cells (Figure 7A). However,
other IL-2Rc chain cytokines can also substitute for exoge-
nous IL-2 in Foxp3 induction [37]. To test whether this could
occur in the absence of CARMA1, we activated Carma1
k/k
CD4
þ T cells in the presence of TGFb and IL-4 (an IL-2Rc
chain cytokine). Exogenous IL-4 induced proliferation and
Foxp3 induction, although, as expected, it was less potent
than exogenous IL-2 [38]. However, neutralizing IL-2 anti-
body abrogated this effect (Figure 7B), indicating that other
IL-2Rc chain cytokines can drive IL-2 production and T cell
proliferation independently of TCR-mediated CARMA1
activation. It has also been reported that CpG DNA or
associated proinﬂammatory molecules can act, in vitro,
directly on T cells to restore TCR-mediated proliferation
and induce CD4
þT cell polarization in cells from Pkch
 / mice
[39]. However, neither proliferation nor Foxp3 induction
occurred in Carma1
k/k T cells cultured with TGFb and CpG,
TNFa, IFNa, or IFNc (Figure 7B).
Treg Cell Suppressor Function Does Not Require CARMA1
It remained unclear whether CARMA1 was required for
Treg suppressor function. In addition to Foxp3, in vitro
generated Treg cells express CD25, CTLA-4, and GITR at high
levels, similar to Treg cells found in vivo. Carma1
k/k Treg cells
generated in vitro express normal levels of these markers
(Figure 7C). Treg cells have the ability to suppress T cell
proliferation by a cell-contact dependent mechanism in vitro
[34]. Both wild-type and Carma1
k/k induced Treg cells,
generated in vitro with IL-2 and TGFb, suppressed the
proliferation of wild-type CD4
þ T cells in a co-culture assay
(Figure 7D). The difference in observed suppression at 1:4
Figure 6. Defective IjB Degradation, JNK Phosphorylation, and BCL10
Stability in Carma1
k/k CD4
þ T Cells
(A) Purified CD4
þ T cells were activated with PMA and ionomycin for the
indicated number of minutes. Expression of indicated proteins and
phosphorylated proteins were determined by Western blotting.
(B) Expression of BCL10 in thymus and lymph node lysates. Phosphory-
lated BCL10 is indicated with open arrows.
These experiments were each repeated at least three times with
consistent results and representative data are presented.
doi:10.1371/journal.pbio.1000051.g006
Figure 5. Elevated TGFb Expression in Carma1
k/k Treg Cells
(A,B) Expression of cell associated TGFb in permeabilized Treg cells (A) in
vivo or (B) generated in vitro for 4 d with TGFb and IL-2.
(C) To measure release of soluble TGFb, equivalent numbers of in vitro
generated Treg cells were cultured without exogenous cytokines for 24 h,
with or without activation by anti-CD3 and anti-CD28. TGFb concen-
tration in the supernatant was measured by ELISA.
doi:10.1371/journal.pbio.1000051.g005
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CARMA1 in Treg Developmentand 1:8 dilutions likely reﬂects the proliferation defect in
Carma1
k/k Treg cells. These results suggest Carma1 is neither
required for TGFb-mediated induction of the Treg pheno-
type, nor for suppressor function.
Carma1
k/k Treg Cells Expand during Mouse
Cytomegalovirus Infection
Peripheral Treg cells comprise a small percentage of
Carma1
k/k CD4
þ T cells in the steady-state. It has been
suggested that peripheral Treg cells may expand during
conditions of lymphopenia [9], at the site of tumors [40], or
in response to pathogens [41]. The absence of thymic-derived
Treg cells in Carma1
k/k mice provides a model to study the
dynamics of peripheral Treg cells during infection. To do this,
we infected Carma1
k/k mice with a pathogen that establishes
persistent infection in mice—mouse cytomegalovirus
(MCMV). Carma1
k/k mice mounted T-dependent B cell
responses that were reduced compared to the wild-type
response (Figure 8A), but sufﬁcient to allow survival without
any signs of virus-induced immunopathology or detectable
virus in the spleen 14 d after infection. Yet, at the peak of the
effector CD4
þ T cell response, 8 d after infection, no Treg
expansion was observed in the spleen (Figure 8B). However,
splenic CD4
þFoxp3
þ Treg cells expanded by an order of
magnitude in Carma1
k/k mice 14 d after MCMV infection
(Figure 8C). MCMV establishes persistent infection in the
salivary glands, and T cells drain from the salivary glands to
the submandibular lymph nodes. Here, Treg expansion was
also observed in Carma1
k/k mice (Figure 8D). No Foxp3
expression was detected in the thymus 8 or 14 d after
infection, suggesting that Treg expansion resulted from either
de novo induction of Foxp3 or expansion of the pre-existing
peripheral Treg pool. Additionally, MCMV infected Carma1
k/k
mice did not develop signs of autoimmune or lymphoproli-
ferative disease when monitored for 80 d after infection.
Discussion
Accumulating evidence suggests that diverse stimuli can
drive proliferation or induction of CD4
þFoxp3
þ Treg cells in
the periphery [20,40–43]. We have shown that cytokines or
MCMV infection can drive Foxp3 induction and peripheral
Treg proliferation in the absence of CARMA1, but found
different requirements for thymic Treg development. Con-
trary to expectations that the Treg deﬁciency observed in mice
lacking components of the CARMA1 pathway reﬂected an
inability to produce IL-2 [33], cytokines produced by wild-
type thymocytes or thymic epithelial cells did not rescue
thymic Foxp3 induction in Carma1
k/k thymocytes in mixed
bone marrow chimeric mice. This may reﬂect the absence of
CD4
þCD25
þ thymocytes capable of responding to IL-2 and
inducing Foxp3 [44] among Carma1
k/k thymocytes. Thus,
Figure 7. Induced Carma1
k/k Treg Cells Generated with TGFb and IL-2 Are Functional
(A) Co-culture of wild-type and Carma1
k/k CD4
þ T cells, activated for 70 h, with or without neutralizing IL-2 antibody.
(B) Purified CD4
þ T cells activated for 70 h, in the presence of TGFb and the indicated molecule.
(C) Expression of CD25, GITR, and CTLA-4 in induced Treg cells.
(D) Co-culture suppressor assay using wild-type or Carma1
k/k induced Treg cells and CFSE-labeled wild-type CD8
þ T cells. The ratio of suppressor to
responder cells is indicated. CD8
þ T cell proliferation is shown.
These experiments were each repeated at least two times with consistent results and representative data are presented.
doi:10.1371/journal.pbio.1000051.g007
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CARMA1 in Treg Developmentunlike Foxp3 induction in peripheral CD4
þT cells, which can
be driven by cytokines without activation of CARMA1,
developing thymocytes require activation of a cell-intrinsic,
CARMA1-dependent signaling pathway(s) that likely includes
the transcription factor NF-jB. CARMA1-mediated NF-jB
activation may act as a survival factor in thymic Treg
development, preventing apoptosis of thymocytes with
certain TCRs or pre-TCRs [28,45] that are destined to
become CD4
þFoxp3
þ Treg cells.
Given the robust T cell expansion observed in Carma1
k/k
mice during MCMV infection, it is perhaps surprising that
they do not develop spontaneous autoimmune disease as a
consequence of thymic Treg deﬁciency. Likewise, deletion of
other genes in the Carma1 pathway—Pkch [46], Bcl10 [46], Tak1
[47,48], Ikkb [49]—impairs Treg development, but does not
result in spontaneous autoimmunity (see Figure S5). Mice
with a Ick-driven CD4-speciﬁc deletion of Tak1 develop colitis
with age, although escaped CD4
þ T cells retaining intact Tak1
might initiate disease in this model [47]. Additionally,
hypomorphic mutations in regulators of TCR-mediated PKCh
activation, linker for T cell activation (Lat) [50], and zeta-
chain-associated protein kinase 70 (Zap70) [51], also block
Treg development. In Carma1
k/k mice, T cells, including any
with potentially auto-reactive TCRs, are normally quiescent,
but can become activated during the ‘‘cytokine storm’’ of
infection. The small Carma1
k/k peripheral Treg pool may also
contribute to dampening T cell responses directed towards
self-antigens or commensal ﬂora and may release more of the
regulatory cytokine TGFb than wild-type Treg cells. Addition-
ally, the impaired B cell function in Carma1-deﬁcient mice
may prevent ampliﬁcation of auto-reactive immune re-
sponses. We also demonstrated that NKT cell, but not
conventional T cell cytokine production occurred normally
without functional CARMA1, suggesting that in the absence
of thymic-derived Treg cells, Carma1
k/k NKT cells do not drive
spontaneous autoimmune disease.
The development of the hematopoietic system and
lymphocyte activation defects were similar in Carma1
k/k mice
and Carma1-knockout mice. Therefore, it was surprising to
ﬁnd reduced protein levels and constitutive phosphorylation
of BCL10 in Carma1
k/k CD4
þ T cells. In CARMA1-deﬁcient
JPM50.6 cells, BCL10 expression is normal [52]. The normal
expression of BCL10 in Carma1
k/k thymocytes, but not lymph
node cells suggests BCL10 degradation may be conﬁned to
mature T and B cells. As the king mutation occurred in a
region of CARMA1 predicted to regulate accessibility of the
CARD domain, we propose a model in which BCL10 is
constitutively recruited to the CARMA1-king protein in
mature T and B cells. This interaction is not sufﬁcient to
assemble the full CARMA1-BCL10-MALT1 signaling complex
or to activate NF-jB, but does allow for BCL10 phosphor-
ylation and the subsequent degradation of BCL10 [27] and
the CARMA1-king protein. As a result, the CARMA1-BCL10-
MALT1 complex cannot be assembled upon TCR stimulation.
The generation of peripheral Treg cells requires TCR
signals in addition to TGFb and IL-2 in vitro. Our data
suggest that peripheral Foxp3 induction may not require
CARMA1-mediated activation of NF-jB, as indicated by the
lack of IjBa degradation or JNK phosphorylation after
activation. When IjBa degradation was induced by culturing
CD4
þ T cells with TNFa [29], Carma1
k/k cells still did not
proliferate, nor did they up-regulate Foxp3 in the presence of
TGFb. Similar to our observations for Carma1
k/k mice,
exogenous IL-2 can also rescue the TCR-mediated prolifer-
ation defect in mice deﬁcient for the NF-jB family members
p50 and c-Rel [53]. T cells from these mice also cannot
produce IL-2, and peripheral CD4
þCD25
þcells are reduced 5-
fold. It will be of interest to determine if thymic Treg cells
develop in these NF-jB deﬁcient mice and whether periph-
eral CD4
þ T cells from these mice induce Foxp3 after
exposure to IL-2 and TGFb.
Recently, two groups reported TGFb-independent Foxp3
induction in vitro when CD4
þ T cells were activated in the
presence of chemical or genetic inhibitors of the phospha-
Figure 8. Peripheral Expansion of Treg Cells in Carma1
k/k Mice after MCMV Infection
(A) MCMV-specific Ig concentrations measured in serum collected 14 d after infection.
(B–D) Foxp3 expression in splenic CD4
þ T cells 8 (B) or 14 (C) d after infection, and in sub-mandibular lymph node CD4
þ T cells 14 (D) d after infection.
Five mice were analyzed in each group. Standard deviation is indicated.
doi:10.1371/journal.pbio.1000051.g008
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CARMA1 in Treg Developmenttidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapa-
mycin (mTOR) signaling axis [18,19]. Weak or transient TCR
stimulation, without co-stimulation, is also postulated to
favor peripheral induction of Foxp3 in vivo [19,43]. However,
Carma1
k/k CD4
þ T cells were less prone than wild-type CD4
þ T
cells to induce Foxp3 when given weak TCR stimulation.
Therefore, our data suggest that unlike the AKT signaling
axis, blockade of CARMA1-dependent signaling does not
favor peripheral Foxp3 induction.
In vivo, we have shown that factors produced during
MCMV infection can stimulate peripheral Treg expansion in
Carma1
k/k mice. Our in vitro data suggest that this expansion
may require IL-2Rc chain cytokines, such as IL-4, to drive IL-
2 production. Expansion of Treg cells may contribute to the
transient immunosuppression that can follow viral infection
[54], and our data suggest these cells may arise peripherally.
Such a response could protect the host against cross-reactive
anti-viral T cells that have the potential to precipitate
autoimmune disease. An alternative but not mutually
exclusive hypothesis holds that MCMV may manipulate the
host immune response to expand virus-speciﬁc Treg cells.
Such a strategy has been well documented for the parasite
Leishmania major [42], and may be utilized by other viruses, for
example Friend leukaemia virus [41]. If these Treg cells
localized to viral reservoirs, they could facilitate persistent
viral infections.
The existence of two pathways for Foxp3 induction allows
for a total Treg pool with two potential speciﬁcities [32].
Thymic Treg cells might primarily express TCRs with
intermediate self-afﬁnity [9], as Foxp3 induction would
require TCR signals strong enough to activate CARMA1
without causing clonal deletion. Tonic signaling through the
TCR along with consumption of cytokines could allow
expansion of thymic Treg cells to ﬁll the Treg niche. The
generation of peripherally induced Treg cells might be driven
by cytokines produced by the innate immune system at
mucosal sites or during infection. In Carma1
 /  mice, myeloid
cells make normal amounts of IL-2, which may support the
peripheral Treg population we observe in Carma1
k/k mice [55].
These induced Treg cells could then prevent T cell responses
to commensal ﬂora and dampen potentially dangerous
responses to pathogens [41] or innocuous antigens [43].
Materials and Methods
Mice, pathogens, and antibodies. We obtained C57BL/6J and Jnk2
 / 
mice from The Jackson Laboratories. We generated king mice at TSRI
using ENU mutagenesis [21]. They have been made available through
the Mutant Mouse Regional Resource Centers (MMRRC:030114-
UCD).
The MCMV smith strain was isolated from the salivary glands of 3-
wk-old infected BALB/c mice. 1 3 10
5 PFU of MCMV was injected IP
per mouse.
The following antibodies were used in this study for ﬂow
cytometry: CD4-APC (L3T4), CD25-FITC (PC61.5), CD45.1-FITC
(A20), CD45.2-APC (104), CD69-APC (H1.2F3), Foxp3-PE (FJK-16s),
GITR-FITC (DTA-1), IFNc-APC (XMG1.2) (eBioscience); CD4-FITC
(L3T4), CTLA-4-FITC (1B8) (Southern Biotech). Intracellular staining
was performed for analysis of CTLA-4, Foxp3, and IFNc. These
antibodies were used for western blotting: BCL10 (Santa Cruz);
CARD11, IjBa, pJNK, JNK, TAK1 (Cell Signaling). Puriﬁed CD3e
(145–2C11) and CD28 (37.51) antibodies (eBioscience) were used at
indicated concentrations for T cell activation. Carboxyl ﬂuorescent
succinimidyl ester (CFSE) labeling was performed by incubating
MACS (Miltenyi Biotech) puriﬁed CD4
þ T cells, CD8
þ OT-I T cells, or
splenic B cells in 5 lM CFSE with 0.1% fetal calf serum in PBS for 10
min.
CD8
þ T cell functional assays. To assess the CD8
þ T cell response,
we immunized mice with 1 3 10
7 c-irradiated (1,500 rad) act-mOVA
splenocytes. 7 d later, 5 310
6 splenocytes were isolated and cultured
with 10 nM SIINFEKL peptide in IMDM media supplemented with
10% FCS (Atlanta Bio). 5 d later, cells were restimulated with 100 nM
SIINFEKL peptide in the presence of brefeldin A. Production of IFN-
c was assessed by intracellular cytokine staining.
To test cross-priming of CD8
þ T cells, lymphoid DCs were
generated by culturing 1 3 10
7 bone marrow cells with 200 ng/ml
human Flt3-ligand (Peprotech) in supplemented IMDM media for 8 d.
1 3 10
5 DCs were then co-cultured with 2 3 10
5 c-irradiated (1,500
rad) Kb
 / ; act-mOVA splenocytes and 1 3 10
5 MACS puriﬁed CFSE
labeled CD8
þ OT-I T cells. CFSE dilution was assessed 3 d later by
ﬂow cytometry.
NKT cell activation. NKT cells were activated by injecting mice IV
with 2 lgo faGalCer. Serum was collected 90 min later, and cytokine
concentration was measured by ELISA (eBioscience).
In vitro T cell activation. MACS puriﬁed splenic CD4
þ T cells were
used to test T cell activation. To measure up-regulation of activation
markers by ﬂow cytometry, cells were activated for 24 h, and then
stained for intra-cellular CD25 and CD69. IL-2 production was
measured by culturing 2310
5 cells/ml under activating conditions in
supplemented IMDM media. Supernatant was harvested at 18 h and
IL-2 was measured by ELISA (eBioscience). T cell proliferation assays
entailed activating CFSE-labeled CD4
þ T cells using 10 lg/ml CD3e
and 1 lg/ml CD28 plate-bound antibodies with or without 100 U/ml
IL-2. CFSE dilution was measured after 4 d by ﬂow cytometry.
Peripheral Treg cells were generated in 24-well plates by culturing 3
310
5 CFSE-labeled CD4
þT cells in plates coated with CD3e and CD28
antibodies with or without IL-2 (R & D Systems) and/or TGFb (R & D
Systems) in supplemented IMDM media. CFSE dilution and intra-
cellular expression of Foxp3 was measured after 4 d of culture. To
examine the effect of other cytokines, 2310
5 CFSE-labeled C57BL/6-
CD45.1
þ and king-CD45.2
þ CD4
þ T cells were co-cultured in plates
coated with 2 lg/ml CD3 and CD28 antibodies in supplemented
IMDM media with 5 ng/ml TGFb and with or without 10 lg/ml
neutralizing IL-2 antibody (JES6–1) (eBioscience). Additionally, CFSE
dilution and Foxp3 induction was assessed in CFSE-labeled CD4
þ T
cells activated by 2 lg/ml CD3 and CD28 plate-bound antibodies in
supplemented IMDM media with 5 ng/ml TGFb and: 100 nM CpG
oligonucleotides (SIGMA), 10 ng/ml IL-4, 10 ng/ml TNFa, 100 U/ml
IFNa, or 100 U/ml IFNc (all cytokines, R & D systems).
For western analysis of T cell signaling, MACS puriﬁed CD4
þ T
cells were activated with 50 ng/ml PMA and 500 ng/ml ionomycin
(SIGMA) for the indicated time. Cells were lysed in a non-ionic buffer
with protease and phosphatase inhibitors for 15 min on ice, then
suspended at a 1:1 ratio in Lamelli sample buffer.
Bone marrow chimeras. Recipient mice were c-irradiated (2 3 500
rads) and injected with 1310
8 donor bone marrow cells. 10 wk later,
lymphoid tissues were harvested, homogenized, stained, and analyzed
by ﬂow cytometry.
In vitro suppressor assays. The Treg suppressor assay was
performed under conditions previously described [34,37]. Brieﬂy,
MACS puriﬁed CD4
þ T cells were cultured in plates coated with 2 lg/
ml CD3 and CD28 antibodies, in 100 U/ml IL-2 (R & D Systems) and 5
ng/ml TGFb (R & D Systems) in supplemented IMDM media. After 4 d,
CD4
þT cells were again MACS puriﬁed. Foxp3 induction was assessed
by ﬂow cytometry, and in all experiments at least 90% of CD4
þT cells
expressed Foxp3. Induced Treg cells were harvested and co-cultured
at indicated ratios with 5310
4 MACS puriﬁed CFSE-labeled CD8
þ T
cells. Also included were 1 3 10
5 T cell-depleted, c-irradiated (3,000
rad) splenocytes as bystander cells and 0.5 lg/ml soluble CD3e
antibody. CFSE dilution was assessed by ﬂow cytometry after 3 d of
co-culture.
MCMV-speciﬁc Ig measurement. To measure the concentration of
MCMV speciﬁc Ig in the serum, 96-well plates were coated with virus,
then blocked in 5% milk. Serum samples were diluted 1:200, then
serially diluted threefold. Anti-Ig HRP conjugated antibodies were
used for detection.
Accession numbers. The Entrez GeneID numbers (http://www.ncbi.
nlm.nih.gov/sites/entrez?db¼gene) for genes and gene products
mentioned in the text are: Aire (11634), Akt (11651), Bcl10 (12042),
Card11 (108723), Cd25 (16184), Cd28 (12487), Cd3e (12501), Cd40
(21939), Cd69 (12515), Cd80 (12519), Cd86 (12524), c-Rel (19696), Ctla-4
(12477), Flt-3 (14255), Foxp3 (20371), Gitr (21936), Ifna (15960), Ifnc
(15978), Ikba (18035), Ikkb (16150), Il-15 (16168), Il-2 (16183), Il-2rb
(16185), Il-2Rc (16186), Il-4 (16189), Jnk2 (26420), Lat (16797), Malt1
(240354), mTor (56717), p50 (18033), Pi3k (18708), Pkch (18761), Tak1
(26409), Tgfb (21803), Tnfa (21926), and Zap70 (22637).
PLoS Biology | www.plosbiology.org March 2009 | Volume 7 | Issue 3 | e1000051 0522
CARMA1 in Treg DevelopmentSupporting Information
Figure S1. Lack of Anti-Chromatin IgG Auto-Antibodies in Aged king
Mice
Serum ELISA measurements from cohorts of homozygous and
heterozygous king mice, aged for 1.5 or 9 mo (n ¼ 5).
Found at doi:10.1371/journal.pbio.1000051.sg001 (190 KB TIF).
Figure S2. B Cell Function Is Impaired by the king Mutation
(A) Basal serum immunoglobulin levels in heterozygous (þ/k) and
Carma1
k/k (k/k) mice. A horizontal bar indicates the mean of each
column. A paired t-test was used to determine statistical signiﬁcance,
*, p , 0.05; **, p , 0.01.
(B) Serum ELISA measurements of OVA-speciﬁc IgG levels 30 d after
immunization with CFA-OVA.
(C)ProliferationofsplenicBcells72hafteractivationwithsolubleanti-
IgM (10 lg/ml), anti-CD40 (10 lg/ml)þIL-4 (10 ng/ml), or LPS (2 lg/ml).
Found at doi:10.1371/journal.pbio.1000051.sg002 (676 KB TIF).
Figure S3. Abnormal Lymphocyte Development in Carma1
k/k Mice
Analysis of lymphocyte populations in the (A) peritoneal cavity, (B–F)
thymus, (G) bone marrow, and (H–L) spleen of 8-wk-old C57BL/6 and
Carma1
k/k mice.
Found at doi:10.1371/journal.pbio.1000051.sg003 (3.39 MB TIF).
Figure S4. CARMA1 Expression in Induced Regulatory T Cells
Puriﬁed CD4
þ T cells were activated with anti-CD3 antibodies and
cultured with IL-2, with or without TGFb, for 90 h. Foxp3 induction
was assessed by ﬂow cytometry, and CARMA1 protein concentration
was measured by western blotting.
Found at doi:10.1371/journal.pbio.1000051.sg004 (594 KB TIF).
Figure S5. T h eR o l eo fT C R - M e d i a t e dN F - jB Activation in
Regulatory T Cell Development
Gray ovals highlight genes for which mutant or knockout mice display
reduced numbers of CD4
þCD25
þ or CD4
þFoxp3
þ Treg cells in the
steady state. Black ovals represent genes for which knockout mice
have normal numbers of CD4
þFoxp3
þ Treg cells. The phenotype of
mice deﬁcient in genes represented by white circles has not been
reported.
Found at doi:10.1371/journal.pbio.1000051.sg005 (259 KB TIF).
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